In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The Anglo ...

AstraZeneca Plc said its experimental obesity pill was well-tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines.

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...

Effectiveness and safety data from Viking’s study, released Sunday at an industry conference, show that an obesity pill could ...

Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...

When AstraZeneca announced it had licensed the experimental, once-daily obesity pill from Eccogene a year ago for up to $2 ...

Viking Therapeutics Inc.’s stock was up up as much as 3.8% early Friday as excitement continued to build about data on the ...

Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies, sending down shares of ...